ArticleScientific reports2024
Identification of novel therapeutic targets for head and neck squamous cell carcinoma through bioinformatics analysis.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Hydrogels in head and neck cancer: Innovations and translational advances in research and therapy.Biomaterials · 2026Review
- Lysine lactylation-mediated post-translational modification: Molecular mechanisms and therapeutic target exploration in tumour drug resistance.Clinical and translational medicine · 2026Review
- SFXN3 Serves as a Predictive Biomarker for Cisplatin Response and Survival in Head and Neck Squamous Cell Carcinoma.Oncology research · 2026Article
- The role of resistin and adiponectin ratios with uric acid in assessing metabolic syndrome in type 2 diabetes.Molecular and cellular biochemistry · 2025Article
- The Multidisciplinary Team in Head and Neck Cancer Reconstruction: A Reference Manual for the Plastic Surgeon.Seminars in plastic surgery · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous cancer with limited therapeutic options. Using publicly available datasets, we identified the WD repeat domain 54 (WDR54) gene as a potential therapeutic target in HNSCC. Gene expression profiling interactive analysis version 2 (GEPIA2) was used to identify genes differentially overexpressed in HNSCC. Our results showed that WDR54, a member of the WD40 repeat domain family, was overexpressed in HNSCC tumor samples. Analysis of three gene expression omnibus datasets showed that WDR54 was overexpressed in tumor samples. Using the UALCAN database, we showed that WDR54 expression in patients with HNSCC at different tumor stages gradually increased with disease progression. We confirmed the association between WDR54 and metastasis using TNMplot.com. WDR54 was overexpressed in metastatic samples compared to that in normal and tumor samples. Kaplan-Meier analysis showed that patients with high WDR54 levels had a poorer prognosis. Additionally, WDR54 expression was correlated with the epidermal growth factor receptor, which is frequently overexpressed in HNSCC. Our findings suggest that WDR54 is a promising biomarker and therapeutic target in HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.